| GTO ID | GTC3446 |
| Trial ID | NCT05864924 |
| Disease | Nasopharyngeal Carcinoma |
| Altered gene | EBV |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BRG01 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma |
| Year | 2023 |
| Country | China |
| Company sponsor | BioSyngen Pte Ltd |
| Other ID(s) | BIOSG-BRG-01 |
| Cohort 1 | |||||||||
|
|||||||||